Haleon stock
HLNNYSEHaleon plc, HealthcareISIN US4055521003
61Score 61 out of 100, Neutral
Price and trend
35 / 100
Price history
−7.6% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.4% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 28).
The price is 19% below its 52-week high. Largest decline in 4 years: 25% (July 2022 to September 2022).
Chart figures for advanced users
- SMA 50$9.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)28
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.57
- The lowest closing price of the last twelve months.
- Resistance$11.27
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Haleon plc belongs to the Drug Manufacturers (Specialty & Generic) industry (United Kingdom) and, with a market value of $40.35B, is number 9 of 78 companies in its industry on MEQIRI.
- American depositary receipt (ADR): 1 ADR = 2 shares.
- In fiscal 2025 it reported revenue of $14.68B (down 1.8% year on year) and earnings of $2.17B (up 13.1%).
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 264 of 714 in Healthcare, median 53.
- The P/E is 18.8 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 25.4).
- Our model puts fair value at $11.14, with the price 18% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 126% of earnings over the last 12 months.Fundamentals 86
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strength is fundamentals, while momentum and technical analysis hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $8.57 and expensive above $15.92 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $12.92 (cash-flow model) and $9.37 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $10.10, at 7.8% it would be $12.70.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Jun 2026, revenue rose 3% on the same quarter a year earlier. Revenue has grown solidly since 2019, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 63%, operating 22%, net 15%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 30 Jul 2026above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 0.42−0.8%
- Revenue
- $15.09B−0.3%
- Earnings per share
- 0.44−2.8%
- Revenue
- $15.61B−0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.0%Guidance of 3% to 5% growth held; high single digit operating profit growth expected again in the second half.
“And that's obviously embedded in our guidance of -- holding our guidance of 3% to 5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Haleon
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Sun Pharmaceutical IndustriesSUNPHARMA.NS $48.71B72
- Jiangsu Hengrui Medicine600276.SS $46.11B70
- Sandoz GroupSDZ.SW $44.42B66
- Jiangsu Hengrui Pharmaceuticals1276.HK $42.51B67
- ZoetisZTS $33.55B75
- Divi's LaboratoriesDIVISLAB.NS $32.21B75
- Hansoh Pharmaceutical Group3692.HK $26.55B79
- ViatrisVTRS $24.14B55
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = £0.7515)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Jun 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.